Check out this Singularity Hub article about Scribe's breakthrough #AHA25 data on our #CRISPR epigenetic and gene editing medicines for heart disease. Thanks to Shelly Fan for covering their potential to revolutionize how cardiometabolic disease is treated 👇 singularityhub.com/2025/11/27/c...

ICYMI, our latest data is out in Fierce Biotech. Read about our lead candidate – epigenetic silencing therapy STX-1150 – and #CRISPR gene editors STX-1200 and STX-1400, designed to safely and durably address the main lipid drivers of heart disease. Article by @megadarren.bsky.social.

Could a single treatment lower heart disease risk by up to 90%? At Scribe, we're engineering #CRISPR gene editing and epigenetic silencing therapies that target major drivers of cardiometabolic disease. Our CEO @benjaminloakes.bsky.social recently shared our progress at #TCT2025.

Our co-founder & CEO @benjaminloakes.bsky.social will present at the 44th Annual J.P. Morgan Healthcare Conference. Join us on Wednesday, January 14 at 8:30 a.m. PT to hear what we have in store for 2026. #JPM2026 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Thanks to Drug Discovery News for the great coverage featuring Scribe CEO @benjaminloakes.bsky.social's thoughts on the current state and future potential of AI-assisted CRISPR technologies. Read the full piece here: www.drugdiscoverynews.com/can-ai-take-...

This week, Scribe’s Computational Genomics & Data Science Team is at @awscloud.bsky.social re:Invent 2025 for the AWS AI League Championship Finals, competing against top AI innovators nationwide. Regional champion Mohit Pandey is representing Scribe after the team’s 1st place win in SF!

As we approach #Thanksgiving, we'd like to celebrate our incredible Scribe team. Their scientific expertise, tireless dedication to advancing our mission, and home-cooked dishes at our annual potluck are just a few of the many reasons we're thankful. Happy Thanksgiving! 🦃

We’re excited to be featured in @longevitytech.bsky.social, where @mrdannysullivan.bsky.social sits down with our CEO @benjaminloakes.bsky.social to discuss how next-gen CRISPR therapies could extend lifespans by revolutionizing the treatment paradigm for CVD. Read the full piece: bit.ly/4riTDZn

📅 Join today's Fierce Biotech Cell & Gene Turning Point event! Our CEO @benjaminloakes.bsky.social will take the virtual stage at 11:30 am PT for a fireside chat exploring how CRISPR could redefine the treatment paradigm for CVD. Register for free now: www.fiercecellandgene.com

We're excited to share breakthrough preclinical data across our cardiometabolic pipeline presented at #AHA25, highlighting our comprehensive strategy to address the key drivers of #ASCVD. Thanks to Fierce Biotech‘s Darren Incorvaia for the feature: www.fiercebiotech.com/research/scr...

Scribe CEO @benjaminloakes.bsky.social will join a fireside chat at Fierce Biotech's Cell & Gene Turning Point event on Thursday, 11/20. He'll discuss how CRISPR-based therapies could help prevent, not just treat, cardiovascular disease. Register for free here: www.fiercecellandgene.com

#AHA25 Scientific Sessions are underway! Don’t miss key presentations by CSO Aarif Khakoo and SVP of Discovery Biology Maria Mirotsou. From #CRISPR gene editing to epigenetic silencing, we’ll share updates on our pipeline of therapies for cardiovascular disease.👇 @ahascience.bsky.social

🥇 Our Computational Genomics & Data Science team won 1ST PLACE in AWS AI League for Startups SF! Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.

📣 #AHA25 is almost here! We’re headed to New Orleans to share the latest on our pipeline of #CRISPR genome editing & epigenetic silencing therapies for cardiometabolic disease. Details below on 4 presentations by our CSO Aarif Khakoo & SVP of Discovery Biology Maria Mirotsou 👇

When it’s spooky season at Scribe, expect our annual #Halloween barbecue, scary and scientific costumes, and treats galore. Happy Halloween to all! 🎃

How can we transform the standard of care for heart disease? ❤️‍🩹 Join us at #TCT2025 this Saturday to hear from our CEO @benjaminloakes.bsky.social, who will share promising #CRISPR gene editing and epigenetic silencing strategies at @crfheart.bsky.social TCT MedTech Innovation Forum.

Missed our presentation on Scribe’s ELXR (epigenetic editor) technology at #ESGCT2025? Catch up with this BioWorld article highlighting how we engineered our ELXR platform for enhanced potency and its therapeutic application in durably targeting PCSK9. www.bioworld.com/articles/725...

Listen to Scribe’s co-founder, Jennifer Doudna, speak to the vision that Scribe was founded on – unlocking #CRISPR to revolutionize the standard of care for cardiometabolic disease. "I really hope that gene editing technology, like CRISPR, becomes a preventative [therapy]..." 🧵

Congrats to our CEO, @benjaminloakes.bsky.social, on being named to BioSpace’s inaugural 40 Under 40 list of exemplary biotech leaders for his vision, innovation, and commitment to advancing next-generation #CRISPR-based therapeutics that improve patient outcomes.

We’re headed to #ESGCT2025 to share our latest #CRISPR #EpigeneticEditing data. Check out our presentation on Thursday, Oct. 9! 🧬 Engineering enhanced epigenetic editors: novel repressor domains drive potent and durable therapeutic gene silencing in non-human primates

Meet Scribe at #CGMesa25 in Phoenix 🌵 Our CFO David Parrot will be onsite at the @alliancerm.bsky.social Cell & Gene Meeting on the Mesa to present updates on our work engineering #CRISPR-based medicines for cardiometabolic disease. Swing by and learn more on Monday, Oct. 6 at 1:45pm MST.

Ahead of #WorldHeartDay, Taylor Swift recently raised an important reminder: heart disease is the leading cause of death, and one person dies from it every 34 seconds. For some, including her father, a routine stress test revealed severe disease early enough to undergo surgery.

Attending the Genome Editing Therapeutics Summit? Join us Sept. 30 for the opening presentation by Kai-Yuan Chen, Scribe's Director of Data Science & Tech Platform, highlighting DeepXE: our deep learning model powering #CRISPR-CasX therapeutic gRNA design. #AI #MachineLearning

An important piece in @forbes.com by Leaps By Bayer highlighting the dangers of high cholesterol, the urgent need for solutions beyond statins, and Scribe’s advances developing #CRISPR gene editing and epigenetic silencing therapies for cardiometabolic disease. www.forbes.com/sites/juerge...

This Thursday, join us at the Oppenheimer Private Life Science Company Showcase for a virtual presentation by our CFO David Parrot. 📅 September 25, 2025 🕗 3:15pm ET 📍 Virtual ✅ Register for the event or reach out to our team at www.scribetx.com/contact

Knowing your #cholesterol could save your life. This National #CholesterolEducationMonth, stay up to date on the impact cholesterol levels have on your risk for heart disease. 👇

Attending the Bank of America Healthcare Trailblazers Private Company Conference in Boston this week? Book a meeting with Scribe CFO David Parrot to learn about our latest updates, data, and approach to advancing #CRISPR for cardiometabolic disease 👉 www.scribetx.com/contact

📣 Presenting new breakthrough data from two of our core platforms 📣 We're proud to showcase the success of our Lp(a)-lowering therapy STX-1200 and novel #AI platform, DeepXE, for next-generation #CRISPR-based therapeutics. More details in our link below 👇

At Scribe, we run on teamwork and purpose – in and out of the lab. #JPMCC 2025 marked our 4th year participating in the global J.P. Morgan Corporate Challenge. Check out our reel for highlights our team captured as they ran through San Francisco, repping our “ELXR” tech! 🧪😉

If you’ll be in New York for the Cantor Global Healthcare Conference, our CEO @benjaminloakes.bsky.social and CFO David Parrot will be on site and available for one-on-one meetings between Sept. 3-5. Interested in connecting? Reach out through our website 👉 www.scribetx.com/contact

At #ESCCongress for the latest on #CRISPR gene editing treatments for cardiometabolic disease? On Monday, our CSO Aarif Khakoo will present late-breaking preclinical data on STX-1200, our novel CRISPR-CasX based gene editing therapy to reduce elevated Lp(a) & CVD risk. Read more 👇

This fall, we are thrilled to present our latest updates on our #CRISPR genetic and epigenetic editing therapies, new machine learning approach, and corporate strategy at several premier conferences. If you’ll be at #ECCongress, #CGMesa25, and others, read on for more details 👇

What does it take to rewrite the story of disease? Our CEO @benjaminloakes.bsky.social‬ shared with @bigthink.com‬ how a mission-driven team like Scribe can redefine what is possible in medicine with #CRISPR. His insights on leadership, innovation, and bold vision 👇 bigthink.com/business/lea...

We’re proud to call Alameda our home and share with the SF Business Times the history of our space (all the way back to WWI and WWII) and ability to invest in world-class talent to help us engineer the future of medicine. Read about our #biotech community: www.bizjournals.com/sanfrancisco...

Deep learning for #CRISPR? We're presenting "DeepXE" at @cshlnews.bsky.social's Genome Engineering: CRISPR Frontiers meeting—the 1st predictive model for on-target activity of our genome editor engineered from CasX. Learn how we're tapping #AI to design efficient gRNAs for therapeutics. #CSHL

📣 New publication alert! Scribe and @ucberkeleyofficial.bsky.social scientists (Zachary Miller, Lokesh Narsineni et al.) have a paper out in the Journal of Controlled Release on a powerful new method for molecular characterization of lipid nanoparticles and mRNA packaging. Learn more below ⬇️

What if your DNA didn’t define your health destiny? In his TEDx Talk, our CEO @benjaminloakes.bsky.social‬ reimagines a future where anyone could walk into their doctor’s office, get treated once, and walk out healthier for life – thanks to next-generation CRISPR-based therapies.

💡 Read The Scientist's latest Innovation Spotlight interviewing our CEO @benjaminloakes.bsky.social about how next-generation #CRISPR #GeneEditing and #EpigeneticEditing tools are reshaping treatment for highly prevalent conditions like cardiometabolic disease. www.the-scientist.com/getting-to-t...

No patient should be left behind. Millions in the U.S. can't wait. Our CEO @benjaminloakes.bsky.social joined the @nplb.bsky.social campaign to share the importance of our work creating & advocating for next-gen medicines, including #CRISPR-based therapies for cardiovascular disease. Learn more ⬇️

“In reality, you’re seeing nothing but good data come out of the CRISPR space. I don’t believe the ability to cure patients is going anywhere.” – @benjaminloakes.bsky.social, Scribe CEO in GEN on delivering the full promise of #CRISPR Read more here and our 🧵: www.genengnews.com/topics/genom...

It’s Day 1 of #BIO2025! Join our CBO Svetlana Lucas this afternoon as she takes the stage for a panel discussion on what to know about partnering early in biopharma. The session starts at 3 p.m. ET in Room 210A. Don’t miss it! ⬇️

Kick off #BIO2025 week with our CBO Svetlana Lucas as she joins biopharma leaders to discuss what makes a platform or modality partnerable—to ultimately bring next-generation therapies to patients. More details 👉 convention.bio.org/program-1/jo...

We're excited to attend #BIO2025! Reach out to set up a meeting with us if you're interested in collaborating to rewrite the story of disease and hearing the latest updates on our #CRISPR genome and epigenome editing technologies and pipeline 👉 www.scribetx.com/contact

In this feature, @barrons.com highlights that “genetic-medicine approaches to PCSK9 are exploring nonpermanent, but long-lasting fixes ... Scribe Therapeutics has reported intriguing results in monkeys from ‘epigenetic’ edits of the molecules that turn genes on and off.”

This month, we presented positive data on our #CRISPR technologies at the 2025 @eassociety.bsky.social and @asgct.bsky.social Annual Meeting. For more details, read our thread and press release below 👇

Attending #ASGCT2025 🧬 in New Orleans? Be sure to check out our first presentation today on novel #CRISPR genome editing strategies using our X-Editor (XE) technology to target mutations in Duchenne Muscular Dystrophy. 👇

Join us at the upcoming @asgct.bsky.social Meeting – we will have two presentations showcasing our ongoing advances to engineer novel in vivo genetic medicines, including a joint session with Prevail Therapeutics (a part of @elilillyandcompany.bsky.social’s Gene Therapy Division). Details below 🧬

🫀 #EASCongress2025 attendees: Don’t miss our presentation tomorrow at 4:00 pm BST! Our CSO Aarif Khakoo will be unveiling data on our #CRISPR epigenetic silencer for LDL-C lowering as part of our work to transform the standard of care for patients with cardiometabolic disease.

We’re pleased to announce the achievement of a success milestone in our collaboration with Prevail Therapeutics, a part of @elilillyandcompany.bsky.social’s Gene Therapy Division, to develop in vivo #CRISPR-based therapeutics for neurological and neuromuscular disorders. Highlights below 🧵

Happy #DNADay25! Today we celebrate the revolutionary discovery of the double helix and ongoing innovations in genomics. 🧬 Scribe is dedicated to unlocking the next frontier of genetics and epigenetics to create novel #CRISPR-based therapies. Learn more: scribetx.com